Dacomitinib (EGFR, ErbB-2, and ErbB4, irreversible inhibitor) was efficient in inhibiting the tumor volume of HNSCC and acted as a radiosensitizing agent in HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.